A Distributed Delay Approach for Modeling Delayed Outcomes in Pharmacokinetics and Pharmacodynamics Studies

This poster demonstrates that the distributed delay approach is general enough to incorporate a wide array of models as special cases including transit compartment models, typical absorption models, and models for describing atypical absorption profiles such as double/multiple-peak phenomenon after oral administration in pharmacokinetics.

Read More
Topics:

Certara’s Best of Blogs 2015

A selection of short essays from our blog, written to empower our customers with biosimulation and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing.

Read More
Topics:

The Simcyp Population Based Simulator®: Architecture, Implementation, and Quality Assurance

Developing a user-friendly platform that can handle a vast number of complex physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) models both for conventional small molecules and larger biologic drugs is a substantial challenge. Over the last decade the Simcyp Population Based Simulator® has gained popularity in major pharmaceutical companies (70% of top 40 – in term […]

Read More
Topics:

The Simcyp population-based ADME simulator®.

The Simcyp® population-based absorption, distribution, metabolism and excretion simulator is a platform and database for ‘bottom-up’ mechanistic modelling and simulation of the processes of oral absorption, tissue distribution, metabolism and excretion of drugs and drug candidates in healthy and disease populations. It combines experimental data generated routinely during preclinical drug discovery and development from in […]

Read More
Topics:

Can Modeling & Simulation Inform Personalized Medicine?

Kevin Feng

Pharma faces an existential crisis. The cost and time lines of developing new medications have been growing exponentially for decades, with no end in sight. Could modeling and simulation approaches be the Next Great Hope for ending this madness and restoring sustainability to drug development? At the same time, can it deliver on the promise of making the dream of personalized medicine a reality? In this blog post, I’ll discuss how modeling and simulation (M&S) is changing drug development and some of the challenges the pharmacometrics community must overcome to make the greatest improvements in treatments for patients.

Read More
Topics: Drug Safety, Model-based Drug Development
Learn More
LinkedIn